Hester Biosciences Limited — Others, 11-07-2025: Shareholders meeting

Hester Biosciences has announced a board meeting on 13 August 2025 to consider the financial results for the quarter and half-year. The company reported steady standalone revenue from operations of INR 286.47 Cr, marginally up from INR 285.16 Cr last year, with a 17% rise in standalone net profit to INR 31.84 Cr. Consolidated revenue stood at INR 311.10 Cr, up from INR 304.55 Cr, while consolidated profit after tax increased 36% to INR 28.83 Cr. The Poultry Healthcare division grew 16% to INR 166.44 Cr, driven by vaccine demand and new product launches, contributing 58% of revenue. The Animal Healthcare segment, including ruminants and pet care, grew 6% to INR 119.88 Cr, supported by government immunisation programs and expanded petcare offerings. Operational efficiency improved with an 8% rise in EBITDA to INR 55.71 Cr and gross margin expansion to 67%. The company reduced standalone borrowings by 28% to INR 105.05 Cr, strengthening its balance sheet. Capital expenditure focused on expanding manufacturing capacity, including Fill-Finish and BSL-3 facilities, though some delays occurred due to project scope changes and approvals. Hester’s subsidiaries in Nepal and Africa contributed positively, with Africa reducing losses significantly and progressing toward breakeven. The Board has recommended a dividend of INR 7 per share (70%). The company continues to invest in R&D, product innovation, and global expansion, particularly in Asia and Africa, while maintaining strong governance and sustainability commitments.